Streetbeat News

Analyst Ratings

LIQT

Lake Street analyst Robert Brown maintains a Buy rating on LiqTech Intl (NASDAQ:LIQT) but lowers the price target from $9 to $6.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 4:26 pm

AVGO

TSM

Taiwan Semiconductor (TSM) and Broadcom (AVGO) are vying to join the trillion-dollar market cap club, driven by AI advancements. TSM has stronger growth potential with a projected market cap of $1.23 trillion, while Broadcom's upside is limited to $934 billion.

Portfolio Pulse from Surbhi Jain

October 10, 2024 | 4:23 pm

BTU

BMO Capital has maintained a Market Perform rating on Peabody Energy while raising its price target from $25 to $26.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 4:22 pm

NEE

Significant investors have shown interest in NextEra Energy (NYSE:NEE) options, with a mix of bullish and bearish sentiments. The options activity suggests a price range of $80 to $95 for NEE in the short term. Analysts have mixed ratings, with a consensus target price of $85.67.

Portfolio Pulse from Benzinga Insights

October 10, 2024 | 4:22 pm

ADMA

High-rolling investors are showing a bearish sentiment on ADMA Biologics (NASDAQ:ADMA) through options trading, with 71% of trades being bearish. The stock is currently down 18.28% at $16.61, and RSI indicators suggest it may be oversold. An analyst from Cantor Fitzgerald has revised the rating to Overweight with a price target of $20.

Portfolio Pulse from Benzinga Insights

October 10, 2024 | 4:22 pm

HMY

Harmony Gold Mining shares rose following an upgrade by JP Morgan from Underweight to Neutral, with a price target increase from $4.9 to $8.2.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 4:22 pm

CVS

The options market shows a bullish sentiment towards CVS Health, with 66% of trades being bullish. Analysts have mixed ratings, with price targets ranging from $62 to $85. CVS Health's stock is currently trading at $66.86, with a recent 1.35% increase.

Portfolio Pulse from Benzinga Insights

October 10, 2024 | 4:22 pm

CSTM

BMO Capital analyst Katja Jancic maintains an Outperform rating on Constellium (NYSE:CSTM) but lowers the price target from $24 to $22.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 4:20 pm

INMD

Needham analyst Mike Matson has reiterated a Hold rating on InMode (NASDAQ:INMD).

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 4:19 pm

ICUI

Needham analyst Mike Matson has reiterated a Hold rating on ICU Medical (NASDAQ:ICUI).

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 4:15 pm